Dapagliflozin (Farxiga) in Patients with Chronic Kidney Disease

Many patients with chronic kidney disease are at a higher risk for severe kidney and heart health issues. The DAPA-CKD trial was designed to see the impact of Dapagliflozin Propanediol, which is sold under the brand name Farxiga, in patients with and without type 2 diabetes who had chronic kidney disease. Read more

Posted in Type II Drugs Other News